(Press-News.org) Scientists at USC have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug-resistant.
The drug, which so far has been tested in the lab on ovarian cancer cells and on mice tumors, was unveiled last month in the Proceedings of the National Academy of Sciences (PNAS).
"We need a new generation of drugs," said Shili Xu, a USC graduate student and lead author of the PNAS paper. "We need to overcome the drug-resistance issue."
The drug is a member of a new class of cytotoxic agents abbreviated as PACMA that was discovered by testing roughly 10,000 chemical compounds on cancer cells in the lab of Nouri Neamati, professor of pharmacology and pharmaceutical sciences at the USC School of Pharmacy, and a co-corresponding author of the paper.
These initial findings led to a collaboration with Nicos Petasis, co-corresponding author of the paper and professor of chemistry at the USC Dornsife College of Letters, Arts and Sciences, with appointments at the School of Pharmacy and the USC Norris Comprehensive Cancer Center of the Keck School of Medicine of USC. This joint effort led to a study of PACMA compounds that was reported last year in the Journal of Medicinal Chemistry.
In order to investigate and optimize the anticancer properties of PACMAs, co-author Alexey Butkevich, a graduate student in the Petasis lab, synthesized more than 80 newly designed compounds. One of these, called PACMA31, was eventually found to be very toxic to ovarian cancer cells and was shown to be a potentially effective drug.
In the PNAS paper, Xu and his co-authors reported that PACMA31 is a potent and selective inhibitor of a protein called Protein Disulfide Isomerase (PDI) that is highly expressed in ovarian cancer.
PACMA31 can be taken orally and accumulates in cancer cells, which means that it is less likely to cause harmful side effects in normal tissues. It is also what is known as an "irreversible" drug, meaning that it permanently latches on to its target, PDI, and refuses to wear off until the protein is degraded.
That irreversibility may result in prolonged duration of drug action that could translate into giving the patients lower doses of drugs.
"We are exploring combination studies in order to find synergy between our drug and first-line therapy for ovarian cancer," Neamati said.
Currently, there are two major types of drugs in the first-line treatment of ovarian cancer: paclitaxel, which hinders cancer cell division by inhibiting the disassembly of microtubules; and carboplatin, which binds to and causes crosslinking of DNA that results in the death of cancer cells.
PACMA31 attacks cancer cells in yet a different way, targeting PDI and thus interrupting the folding process during which proteins assume the shapes that allow them to function properly. Accumulation of misfolded proteins in a cell causes cellular stress and eventually cancer cell death.
Because PACMA31's strategy is different than that of current anticancer drugs, it has the potential to help patients who do not respond to paclitaxel or cisplatin.
"When the patient has no other choice, we could potentially treat them with our drug," Neamati said.
Other co-authors of the PNAS paper included Roppei Yamada, Yu Zhou, Bikash Debnath and Professors Roger Duncan and Ebrahim Zandi. Additional contributors to the PACMA project and co-authors to the team's first paper included Xuefei Cao, Melissa Millard, Srinivas Odde, Nick Mordwinkin, Rambabu Gundla and Professor Stan Louie.
"The discovery of this new drug and its novel mechanism of action is a great example of the power of interdisciplinary collaborations between chemists, biologists, pharmacologists and other biomedical researchers," Petasis said.
The drug will still require additional testing, but so far it appears to be nontoxic and effective at halting tumor growth. It may also have potential for treating other types of cancer, Neamati noted.
"Obviously, we think that it will go beyond ovarian cancer," he said.
INFORMATION:
Funding for the research came from the USC Zumberge Research and Innovation Fund, the American Chemical Society, the William Cockrell Endowed Cancer Research Fund and the U.S. Department of Defense Ovarian Cancer program.
END
New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting. The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way.
Wenhui Hu and colleagues point out that existing drugs for AD provide only "minimal" relief of memory loss and other symptoms, creating an urgent need for new medicines that actually combat ...
If applied to the $5-billion-per-year dietary supplement industry, "quality by design" (QbD) — a mindset that helped revolutionize the manufacture of cars and hundreds of other products — could ease concerns about the safety and integrity of the herbal products used by 80 percent of the world's population. That's the conclusion of an article in ACS' Journal of Natural Products.
Ikhlas Khan and Troy Smillie explain that the U.S. Food and Drug Administration (FDA) regulates dietary supplements as a category of foods, rather than drugs. Manufacturers are responsible for ...
Scientists are describing what may be a "complete solution" to cleaning up oil spills — a superabsorbent material that sops up 40 times its own weight in oil and then can be shipped to an oil refinery and processed to recover the oil. Their article on the material appears in ACS' journal Energy & Fuels.
T. C. Mike Chung and Xuepei Yuan point out that current methods for coping with oil spills like the 2010 Deepwater Horizon disaster are low-tech, decades-old and have many disadvantages. Corncobs, straw and other absorbents, for instance, can hold only about 5 times their ...
Billions of people around the world today will unknowingly perform a chemical reaction first reported 100 years ago. And the centennial of the Maillard reaction — which gives delightful flavor to foods ranging from grilled meat to baked bread to coffee — is the topic of a fascinating article in the current edition of Chemical & Engineering News. C&EN is the weekly news magazine of the American Chemical Society, the world's largest scientific society.
Sarah Everts, C&EN senior editor, explains in the article that French chemist Louis-Camille Maillard took a first stab ...
Certificate of Need, a form of state government regulation designed to keep mortality rates and health care costs down, appears to do neither for heart bypass surgery, according to a health economics researcher at Rice University and Baylor College of Medicine (BCM). Her findings are reported in an article appearing in today's online edition of the journal Medical Care Research and Review.
Lead author Vivian Ho, the chair in health economics at Rice University's Baker Institute for Public Policy and a professor of medicine at BCM, found that states that removed Certificate ...
CAMBRIDGE, MA -- The colorful leaves piling up in your backyard this fall can be thought of as natural stores of carbon. In the springtime, leaves soak up carbon dioxide from the atmosphere, converting the gas into organic carbon compounds. Come autumn, trees shed their leaves, leaving them to decompose in the soil as they are eaten by microbes. Over time, decaying leaves release carbon back into the atmosphere as carbon dioxide.
In fact, the natural decay of organic carbon contributes more than 90 percent of the yearly carbon dioxide released into Earth's atmosphere ...
After a series of Philadelphia hospitals started closing their maternity units in 1997, infant mortality rates increased by nearly 50 percent over the next three years. The mortality rates subsequently leveled off to the same rate as before the closures, but pediatric researchers say their results underscore the need for careful oversight and planning by public health agencies in communities experiencing serious reductions in obstetric services.
Between 1997 and 2007, 9 of 19 obstetric units closed in Philadelphia, resulting in 40 percent fewer obstetric beds. Other research ...
A simple new test, in which the patient swallows a string, can monitor treatment of eosinophilic esophagitis as effectively as an invasive, expensive and uncomfortable procedure that risks complications, particularly in children.
Researchers from the University of Illinois at Chicago College of Medicine, working in collaboration with clinician-investigators at the University of Colorado Denver/Children's Hospital Colorado and Lurie Children's Hospital in Chicago, reported their findings in a study published recently online in the journal Gut.
Eosinophilic esophagitis, ...
MAYWOOD, Ill. – Gender-specific group therapy is effective for treating depressed women with Type 2 diabetes, according to a study published in the latest issue of the Annals of Behavioral Medicine and funded by the National Institute of Nursing Research. Evidence suggests that antidepressants may disrupt blood-sugar control and can be associated with increased weight gain; therefore, other treatment options are needed for depression.
"Using antidepressants to treat depression, although important, can be associated with side effects that make compliance an issue for people ...
Amsterdam, The Netherlands, October 3, 2012 – Milk consumption has been linked to improved health, with decreased risks of diabetes, metabolic syndrome, and colon cancer. A group of scientists in Sweden found that lactoferricin4-14 (Lfcin4-14), a milk protein with known health effects, significantly reduces the growth rate of colon cancer cells over time by prolonging the period of the cell cycle before chromosomes are replicated. In a new study, investigators report that treatment with Lfcin4-14 reduced DNA damage in colon cancer cells exposed to ultraviolet (UV) light. ...
